Bank Lowers Estimate, Valuation on Illumina's Stock | GenomeWeb

NEW YORK (GenomeWeb News) – Leerink Swann analyst Isaac Ro today lowered the bank's estimates and valuation on Illumina.

He lowered the estimate on Illumina's 2010 earnings per share to $1.03 from his previous estimate of $1.18, based on the assumption that the firm's R&D and SG&A spending will increase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.